We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$440M
1-Year Est. Return
109.12%
This Fund
S&P 500
This Quarter
Est. Return
+32.61%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$439M
AUM Growth
+$21.9M
(+5.3%)
Cap. Flow
-$50M
Cap. Flow
% of AUM
-11.37%
Top 10 Holdings %
Top 10 Hldgs %
49.48%
Holding
86
New
10
Increased
12
Reduced
30
Closed
14
Top Buys
| 1 |
AtriCure
ATRC
|
+$4.87M |
| 2 |
Insulet
PODD
|
+$2.97M |
| 3 |
KALV
KalVista Pharmaceuticals
KALV
|
+$2.75M |
| 4 |
Perspective Therapeutics
CATX
|
+$2.65M |
| 5 |
Larimar Therapeutics
LRMR
|
+$2.59M |
Top Sells
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$15.2M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
+$5.74M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
+$5.31M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$5.25M |
| 5 |
State Street SPDR S&P Biotech ETF
XBI
|
+$4.9M |
Sector Composition
| 1 | Healthcare | 86.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
State Street SPDR S&P Biotech ETF
XBI
$10.6B
| $40.9M | 9.31% |
431,215
-52,785
| -11% | -$4.9M |
|
2
Stereotaxis
STXS
$161M
| $35.7M | 8.13% |
13,680,554
| – | – |
|
3
Cytokinetics
CYTK
$11.2B
| $27.9M | 6.35% |
398,100
-1,900
| -0.5% | -$147K |
|
4
IDEAYA Biosciences
IDYA
$3.54B
| $19.6M | 4.46% |
446,341
-70,000
| -14% | -$3.01M |
|
|
MRUS
5
DELISTED
Merus
MRUS
| $17.1M | 3.89% |
378,995
-75,875
| -17% | -$3.08M |
|
6
Revolution Medicines
RVMD
$39.2B
| $16.5M | 3.76% |
511,894
| – | – |
|
7
Viking Therapeutics
VKTX
$4.39B
| $15.9M | 3.62% |
194,117
-54,100
| -22% | -$2.41M |
|
8
Syndax Pharmaceuticals
SNDX
$2.08B
| $15.7M | 3.57% |
659,574
-83,000
| -11% | -$1.85M |
|
9
iShares Biotechnology ETF
IBB
$9.24B
| $14.1M | 3.2% |
102,500
| – | – |
|
10
Ascendis Pharma A/S
ASND
$17.6B
| $14M | 3.18% |
92,472
-31,000
| -25% | -$4.42M |
|
11
Xenon Pharmaceuticals
XENE
$6.55B
| $11.8M | 2.68% |
273,739
-3,000
| -1% | -$138K |
|
|
DAWN
12
DELISTED
Day One Biopharmaceuticals
DAWN
| $11M | 2.51% |
666,463
-20,000
| -3% | -$299K |
|
|
BPMC
13
DELISTED
Blueprint Medicines
BPMC
| $10.1M | 2.31% |
106,763
-4,100
| -4% | -$352K |
|
14
Neurocrine Biosciences
NBIX
$17.3B
| $9.88M | 2.25% |
71,615
-1,000
| -1% | -$137K |
|
|
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
| $9.57M | 2.18% |
806,973
+205,941
| +34% | +$2.75M |
|
16
Tandem Diabetes Care
TNDM
$1.05B
| $9.14M | 2.08% |
258,208
+37,500
| +17% | +$1M |
|
17
DexCom
DXCM
$28.1B
| $9.09M | 2.07% |
65,552
-2,000
| -3% | -$251K |
|
18
Kura Oncology
KURA
$1.01B
| $8.8M | 2% |
412,663
-80,021
| -16% | -$1.56M |
|
|
19
AtriCure
ATRC
$1.75B
| $8.24M | 1.88% |
271,029
+145,500
| +116% | +$4.87M |
|
|
MORF
20
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $8.16M | 1.86% |
231,748
| – | – |
|
21
Axogen
AXGN
$2.06B
| $7.55M | 1.72% |
935,894
| – | – |
|
22
Biohaven
BHVN
$2.24B
| $6.49M | 1.48% |
118,730
-50,042
| -30% | -$2.48M |
|
|
TSVT
23
DELISTED
2seventy bio
TSVT
| $6.44M | 1.47% |
1,204,051
-243,414
| -17% | -$1.14M |
|
24
Edgewise Therapeutics
EWTX
$4.39B
| $5.59M | 1.27% |
306,197
-143,187
| -32% | -$2.28M |
|
25
Alector
ALEC
$167M
| $5.5M | 1.25% |
912,928
+303,023
| +50% | +$1.98M |
|
Similar funds
FGWP
STCG
SCP
CAAM
AWM
HCM
CPW
DWML